secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-05-27T20:30:41+00:00
Accession:  0001104659-26-066974
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma receives Nasdaq delisting notice; appeals filed
----------------------------------------------------------------

- On May 20, 2026, Nasdaq notified Liminatus Pharma it failed to regain compliance with $50M MVLS and $15M MVPHS requirements.
- Trading suspension of common stock (LIMN) and warrants (LIMNW) set for May 29, 2026 unless appeal filed by May 27, 2026.
- On May 26, 2026, Company requested a hearing before Nasdaq Hearings Panel, which stays delisting pending hearing.
- Company previously disclosed non-compliance on Nov 19, 2025 and had 180-day cure period ending May 18, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/tm2615785d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-066974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer